This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

How Will Colgate-Palmolive (CL) Stock Be Affected By Total Toothpaste Ingredient Allegedly Linked To Hormones, Cancer?

NEW YORK (TheStreet) -- Shares of Colgate-Palmolive Co.  (CL - Get Report) are slightly higher as it was reported that the chemical triclosan has been linked to cancer-cell growth and disrupted development in animals, Bloomberg reports. 

Regulators are reviewing whether it’s safe to put in soap, cutting boards and toys. Consumer companies are phasing it out.

In May, Minnesota voted to ban it in many products.

Must Read: Warren Buffett’s 25 Favorite Stocks

 
At the same time, millions of Americans are putting it in their mouths every day, by way of a top-selling toothpaste that uses the antibacterial chemical to head off gum disease -- Colgate's Total,  Bloomberg noted.
 
 
Total is safe, Colgate says, citing the rigorous FDA process that led to the toothpaste’s 1997 approval as an over-the-counter drug.
 

A closer look at that application process, however, reveals that some of the scientific findings Colgate put forward to establish triclosan’s safety in toothpaste weren’t black and white -- and weren’t, until this year, available to the public, Bloomberg said.

 TheStreet Ratings team rates COLGATE-PALMOLIVE CO as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:
 

"We rate COLGATE-PALMOLIVE CO (CL) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • CL's revenue growth has slightly outpaced the industry average of 5.8%. Since the same quarter one year prior, revenues slightly increased by 0.1%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • The gross profit margin for COLGATE-PALMOLIVE CO is rather high; currently it is at 61.24%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 14.29% is above that of the industry average.
  • Net operating cash flow has slightly increased to $569.00 million or 3.83% when compared to the same quarter last year. In addition, COLGATE-PALMOLIVE CO has also modestly surpassed the industry average cash flow growth rate of -1.17%.
  • COLGATE-PALMOLIVE CO has improved earnings per share by 11.7% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, COLGATE-PALMOLIVE CO reported lower earnings of $2.39 versus $2.58 in the prior year. This year, the market expects an improvement in earnings ($2.97 versus $2.39).
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500, but is less than that of the Household Products industry average. The net income increased by 10.9% when compared to the same quarter one year prior, going from $561.00 million to $622.00 million.
  • You can view the full analysis from the report here: CL Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Submit an article to us!
SYM TRADE IT LAST %CHG
CL $67.45 -0.60%
GOOG $532.12 -1.60%
TSLA $233.05 1.10%
YHOO $41.30 -1.80%
AAPL $126.42 -1.80%

Markets

DOW 17,947.39 -123.01 -0.68%
S&P 500 2,089.50 -24.99 -1.18%
NASDAQ 4,941.4750 -75.4540 -1.50%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs